Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016; 22(3): 1078-1087 [PMID: 26811648 DOI: 10.3748/wjg.v22.i3.1078]
Corresponding Author of This Article
Walid Saliba, MD, MPH, Department of Community Medicine and Epidemiology, Carmel Medical Center, 7 Michal St. Haifa 34362, Israel. saliba_wa@clalit.org.il
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 21, 2016; 22(3): 1078-1087 Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1078
Role of antibiotics for treatment of inflammatory bowel disease
Orna Nitzan, Mazen Elias, Avi Peretz, Walid Saliba
Orna Nitzan, Infectious Disease Unit, Baruch-Padeh Medical Center, Poriya 15208, Israel
Mazen Elias, Department of Internal Medicine C, Ha’Emek Medical Center, Afula 18101, Israel
Mazen Elias, Walid Saliba, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel
Avi Peretz, Clinical Microbiology Laboratory, Baruch-Padeh Medical Center, Poriya 15208, Israel
Walid Saliba, Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa 34362, Israel
Author contributions: All authors contributed equally to this work.
Conflict-of-interest statement: No potential conflict of interest or disclosures declared.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Walid Saliba, MD, MPH, Department of Community Medicine and Epidemiology, Carmel Medical Center, 7 Michal St. Haifa 34362, Israel. saliba_wa@clalit.org.il
Telephone: +972-4-8250474 Fax: +972-4-834435
Received: March 17, 2015 Peer-review started: March 19, 2015 First decision: June 25, 2015 Revised: July 6, 2015 Accepted: November 13, 2015 Article in press: November 13, 2015 Published online: January 21, 2016 Processing time: 273 Days and 2.9 Hours
Core Tip
Core tip: The gut microbiota plays an important role in the pathogenesis and complications of inflammatory bowel disease. Antibiotics may influence the course of inflammatory bowel disease by decreasing concentrations of bacteria in the gut lumen and altering the composition of intestinal microbiota. In Crohn’s disease, antibiotics may have a modest effect in decreasing disease activity and achieving remission, are more effective in patients with disease involving the colon, and are useful in the treatment of suppurative complications. Data is more sparse and less conclusive for the treatment of ulcerative colitis, though there might be some benefit in antibiotic treatment. Side effects, the risk of Clostridium dificile infection, and increasing antibiotic resistance should be considered. Further studies are needed to define the role of antibiotic treatment in inflammatory bowel diseases.
